Vyvanse (lisdexamfetamine) is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, so additional prescribing safeguards are put in place
1 As of 2025, roughly 10 million Americans 2 are on GLP-1s, for both treatment of type 2 diabetes and weight loss, and that number is expected to reach 25 million by 2030
We currently offer a dedicated Orforglipron-related product portfolio, designed to support early development, scale-up, and commercial readiness
Diabetes Care 45:27532786 Dormandy JA, Charbonnel B, Eckland DJA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial
To view or add a comment, sign in EU Approval Is Sought for Teclistamab Monotherapy in R/R Myeloma After 1 Line of Therapy Key Takeaways MajesTEC9 met PFS benefit with HR 0.29 versus SOC PVd or Kd, and showed OS HR 0.60
GLP-1 has been shown to attenuate meal-induced gastric antral propagated contractions while increasing pyloric tone (159, 160)
